Search

One hundred and twenty-eight patients with iron deficiency anemia were treated with a new intramuscular iron preparation, iron-sorbitol-citric acid. One group of 10 patients received a total of 1000 mg. each of elemental iron intramuscularly. All obtained a rise in hemoglobin of over 2.1 g. %, an elevation of serum iron, and a reticulocyte response over 6%. A second larger group of subjects consisted of 113 prenatal and five gynecologic patients; these received an average total dose of 1050 mg. and 1020 mg., respectively, and the average increase in hemoglobin ranged from 1.6 g. % to 2.5 g. %.None of the patients developed significant side effects after injection or permanent staining at the site of injection. Three patients experienced a transient ache at the injection site, and three developed local urticaria-like reactions lasting 24 hours.This new preparation appears to be a safe and clinically effective therapeutic agent in situations in which parenteral iron is indicated.

In 72 pregnant women with culture-proved vaginal candidiasis, and an equal number of controls matched for parity, size, stage of gestation and age, the intravenous glucose tolerance curves were compared using Silverstone's method. The results in both study and control groups did not differ and resembled closely those in Silverstone's series. Half the study group were treated using nystatin alone, while the other half also received tolbutamide. The cure rate was equal in the two groups. Candidiasis in pregnancy does not appear to be related to altered glucose metabolism nor does the addition of this hypoglycemic drug (tolbutamide) improve results. No ill effects, fetal or maternal, were apparent following the use of tolbutamide.